Genetics and Cannabinoid Response for Cannabis Use Disorder

Phase 1

Waitlist Available

Led By Deepak D'Souza, MD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Ages 18-60 years old

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured at baseline, 45 minutes, and 165 minutes after the start of the initial thc/placebo drug infusion.

Summary

This trial focuses on how genetic factors influence a person's vulnerability to cannabis use disorder, psychosis, and cognitive impairment. The study aims to understand how genetics play a role in addiction, response to cannabinoids,

Who is the study for?

This trial is for people aged 18-60 who have used cannabis and may struggle with addiction (CanUD) or have experienced psychosis. It's not for those with major health issues, no history of cannabis use, or pregnant individuals.

What is being tested?

Researchers are testing the effects of Delta-9-THC (the active component in cannabis) against a placebo to understand how genetics influence addiction, response to cannabinoids, and potential treatments for CanUD.

What are the potential side effects?

Delta-9-THC can cause altered senses and mood changes, impaired body movement, difficulty thinking and problem-solving, impaired memory and hallucinations. The severity varies among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 60 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured at baseline, 45 minutes, and 165 minutes after the start of the initial thc/placebo drug infusion.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured at baseline, 45 minutes, and 165 minutes after the start of the initial thc/placebo drug infusion.

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at baseline, 45 minutes, and 165 minutes after the start of the initial thc/placebo drug infusion. for reporting.